Search





Search





Markets
/
Stocks
/
nasdaq-algs
/

Aligos Therapeutics Inc

ALGS

Add to Watchlist

5.710USD

-0.980-14.65%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

35.33MMarket Cap

LossP/E TTM



Aligos Therapeutics Inc

5.710

-0.980-14.65%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aligos Therapeutics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Aligos Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 122 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 65.80.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aligos Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

122 / 382

Overall Ranking

248 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Aligos Therapeutics Inc Highlights

StrengthsRisks

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.19M.

Fairly Valued

The company’s latest PE is -0.58, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.82M shares, decreasing 35.07% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 85.44K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.36.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

65.800

Target Price

+883.56%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Aligos Therapeutics Inc is 5.60, ranking 336 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 2.83M, representing a year-over-year increase of 809.97%, while its net profit experienced a year-over-year increase of 153.47%.

Score

Industry at a Glance

Previous score

5.60

Change



Financials

6.19

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.86

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.13

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Aligos Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Aligos Therapeutics Inc is 8.75, ranking 23 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.58, which is -49.32% below the recent high of -0.30 and -910.11% above the recent low of -5.89.

Score

Industry at a Glance

Previous score

8.75

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 122/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Aligos Therapeutics Inc is 8.40, ranking 127 out of 382 in the Biotechnology & Medical Research industry. The average price target is 55.00, with a high of 175.00 and a low of 36.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

65.800

Target Price

+883.56%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Aligos Therapeutics Inc

ALGS

CRISPR Therapeutics AG

CRSP

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Aligos Therapeutics Inc is 5.44, ranking 318 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.52 and the support level at 5.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.41

Change

-0.97

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.045

Neutral

RSI(14)

38.076

Neutral

STOCH(KDJ)(9,3,3)

38.623

Sell

ATR(14)

0.500

High Vlolatility

CCI(14)

-120.715

Sell

Williams %R

97.490

Oversold

TRIX(12,20)

-0.587

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

6.350

Sell

MA10

6.338

Sell

MA20

6.313

Sell

MA50

6.982

Sell

MA100

7.533

Sell

MA200

8.472

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Aligos Therapeutics Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 52.29%, representing a quarter-over-quarter decrease of 33.43%. The largest institutional shareholder is James Simons, holding a total of 85.44K shares, representing 1.59% of shares outstanding, with 112.97% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Deep Track Capital LP

444.11K

Roche Holding AG

441.04K

-0.00%

Alyeska Investment Group, L.P.

412.00K

Sio Capital Management, LLC

335.94K

Woodline Partners LP

289.17K

-38.24%

Marshall Wace LLP

268.66K

Crestline Investors, Inc.

139.42K

Two Sigma Investments, LP

93.65K

+140.16%

Renaissance Technologies LLC

Star Investors

85.44K

+55.30%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aligos Therapeutics Inc is 2.45, ranking 216 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.30. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Aligos Therapeutics Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.